KR20230117192A - 안구 질환을 치료하기 위한 조성물 및 방법 - Google Patents

안구 질환을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20230117192A
KR20230117192A KR1020237022463A KR20237022463A KR20230117192A KR 20230117192 A KR20230117192 A KR 20230117192A KR 1020237022463 A KR1020237022463 A KR 1020237022463A KR 20237022463 A KR20237022463 A KR 20237022463A KR 20230117192 A KR20230117192 A KR 20230117192A
Authority
KR
South Korea
Prior art keywords
antibody
seq
amino acid
faba
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237022463A
Other languages
English (en)
Korean (ko)
Inventor
아니타 그로벌
로리 테일러
테드 예드녹
Original Assignee
애넥슨, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애넥슨, 인코포레이티드 filed Critical 애넥슨, 인코포레이티드
Publication of KR20230117192A publication Critical patent/KR20230117192A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020237022463A 2020-12-04 2021-12-03 안구 질환을 치료하기 위한 조성물 및 방법 Pending KR20230117192A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121629P 2020-12-04 2020-12-04
US63/121,629 2020-12-04
PCT/US2021/061755 WO2022120137A1 (en) 2020-12-04 2021-12-03 Compositions and methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
KR20230117192A true KR20230117192A (ko) 2023-08-07

Family

ID=81853584

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237022463A Pending KR20230117192A (ko) 2020-12-04 2021-12-03 안구 질환을 치료하기 위한 조성물 및 방법

Country Status (11)

Country Link
US (1) US20240059765A1 (https=)
EP (1) EP4255485A4 (https=)
JP (1) JP2023551734A (https=)
KR (1) KR20230117192A (https=)
CN (1) CN116782940A (https=)
AU (1) AU2021391800A1 (https=)
CA (1) CA3200976A1 (https=)
CL (1) CL2023001596A1 (https=)
IL (1) IL303289A (https=)
MX (1) MX2023006591A (https=)
WO (1) WO2022120137A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
WO2017091719A1 (en) 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
WO2023114763A1 (en) 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof
KR20250006238A (ko) * 2022-04-29 2025-01-10 애넥슨, 인코포레이티드 안구 질환을 치료하기 위한 조성물 및 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) * 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
WO2017091719A1 (en) * 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof

Also Published As

Publication number Publication date
AU2021391800A1 (en) 2023-06-22
CN116782940A (zh) 2023-09-19
CL2023001596A1 (es) 2024-01-19
JP2023551734A (ja) 2023-12-12
EP4255485A4 (en) 2025-05-14
US20240059765A1 (en) 2024-02-22
CA3200976A1 (en) 2022-06-09
EP4255485A1 (en) 2023-10-11
MX2023006591A (es) 2023-08-11
WO2022120137A1 (en) 2022-06-09
IL303289A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
US20250002567A1 (en) Anti-complement factor c1q fab fragments and uses thereof
US20240059765A1 (en) Compositions and methods for treating ocular diseases
JP7499760B2 (ja) 脳損傷を治療するための組成物及び方法
SA111320266B1 (ar) أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني
IL296528A (en) Tie2-binding agents and methods of use
KR20200143718A (ko) 이식편 거부반응 예방에 사용하기 위한 항-cd40 항체
KR20200074993A (ko) 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체
AU2017299579A1 (en) Compositions and methods for treating frontotemporal dementia
JP2026028257A (ja) 血液障害を処置するための組成物及び方法
US20230159637A1 (en) Methods of use of anti-trem2 antibodies
US20250230225A1 (en) Compositions and methods for treating muscular dystrophy
US20250313614A1 (en) Compositions and methods for treating ocular diseases
EA050212B1 (ru) Композиции и способы лечения болезней глаз
HK40101076A (zh) 用於治疗眼部疾病的组合物和方法
HK40121733A (zh) 用於治疗眼部疾病的组合物和方法
JP2025533847A (ja) 抗ｃ１ｑ抗体のための製剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230703

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241203

Comment text: Request for Examination of Application